Showing 1 - 5 results of 5 for search 'Omid Hamid', query time: 0.02s Refine Results
  1. 1
    Application of random survival forest for competing risks in prediction of cumulative incidence function for progression to AIDS

    Application of random survival forest for competing risks in prediction of cumulative incidence function for progression to AIDS by Omid Hamid, Mahtab Tapak, Jalal Poorolajal, Payam Amini, Leili Tapak

    Published 2022-03-01
    Get full text
    Article
    Save to List
    Saved in:
  2. 2
    CX-072 (pacmilimab), a Probody PD-L1 inhibitor, in combination with ipilimumab in patients with advanced solid tumors (PROCLAIM-CX-072): a first-in-human, dose-finding study

    CX-072 (pacmilimab), a Probody PD-L1 inhibitor, in combination with ipilimumab in patients with advanced solid tumors (PROCLAIM-CX-072): a first-in-human, dose-finding study by Omid Hamid, Fiona Thistlethwaite, Johanna Bendell, Ruth Plummer, Patrick A Ott, Rachel E Sanborn, Karen A Autio, Valentina Boni, Elisabeth GE de Vries, Javier Garcia-Corbacho, Daniel C Cho, Mark Stroh, Lawrence Lu

    Published 2021-07-01
    Get full text
    Article
    Save to List
    Saved in:
  3. 3
    Long-term survival follow-up for tebentafusp in previously treated metastatic uveal melanoma

    Long-term survival follow-up for tebentafusp in previously treated metastatic uveal melanoma by Jessica C Hassel, Alexander N Shoushtari, Omid Hamid, Takami Sato, Paul Nathan, Marcus O Butler, Jason J Luke, Richard D Carvajal, Leonel Hernandez-Aya, Douglas B Johnson, Laura Collins, Enrique Espinosa, Joseph J Sacco, Serge Leyvraz, Alexandra Ikeguchi, Matthew Rioth, Chris Holland, Josep M Piulats

    Published 2024-06-01
    Get full text
    Article
    Save to List
    Saved in:
  4. 4
    Efficacy and safety of lifileucel, a one-time autologous tumor-infiltrating lymphocyte (TIL) cell therapy, in patients with advanced melanoma after progression on immune checkpoint inhibitors and targeted therapies: pooled analysis of consecutive cohorts of the C-144-01 study

    Efficacy and safety of lifileucel, a one-time autologous tumor-infiltrating lymphocyte (TIL) cell therapy, in patients with advanced melanoma after progression on immune checkpoint... by Jessica C Hassel, James Larkin, Madan Jagasia, Harriet Kluger, Omid Hamid, Jeffrey Weber, Jason Chesney, Amod Sarnaik, John M Kirkwood, Eric Whitman, Martin Wermke, Evidio Domingo-Musibay, Theresa Medina, Sajeve Thomas, Wen Shi, Xiao Wu, Nikhil I Khushalani, Parameswaran Hari, Marlana Orloff, Mike Cusnir, Giao Q Phan, Andrew J S Furness, Michael E Egger, Friedrich Graf Finckenstein, Giri Sulur

    Published 2022-12-01
    Get full text
    Article
    Save to List
    Saved in:
  5. 5
    Overall survival at 5 years of follow-up in a phase III trial comparing ipilimumab 10 mg/kg with 3 mg/kg in patients with advanced melanoma

    Overall survival at 5 years of follow-up in a phase III trial comparing ipilimumab 10 mg/kg with 3 mg/kg in patients with advanced melanoma by Dirk Schadendorf, Ralf Gutzmer, Caroline Robert, Celeste Lebbe, Gabriella Liszkay, Inge Marie Svane, Omid Hamid, Paolo Antonio Ascierto, Catriona McNeil, Claus Garbe, Michele Maio, Vanna Chiarion-Sileni, Luc Thomas, Andrzej Mackiewicz, Carmen Loquai, Ana Arance, Piotr Rutkowski, Laurent Mortier, Lars Bastholt, Brigitte Dreno, Marta Nyakas, Jean-Jacques Grob, Michael Smylie, Christoph Hoeller, Virginia Ferraresi, Florent Grange, Joanna Pikiel, Fareeda Hosein, Burcin Simsek, Michele Del Vecchio

    Published 2020-05-01
    Get full text
    Article
    Save to List
    Saved in:

Search Tools: